Mexiletine in refractory ventricular arrhythmias

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The antiarrhythmic efficacy of mexiletine was evaluated in 28 subjects with recurrent ventricular tachycardia or fibrillation (22 subjects) or with symptomatic complex ventricular ectopy (six subjects). In all, either the arrhythmia was refractory to other drugs, or such therapy was not tolerated. Response to mexiletine was assessed by continuous ECGs, and in five cases by programmed electrical stimulation. Mexiletine abolished the arrhythmia in 12 cases, but was not tolerated long-term in four. Mexiletine was ineffective in 10 subjects. Seven subjects had significant adverse reactions during short-term dosing; in six, mexiletine was discontinued because of adverse effects after the first few doses so efficacy was not evaluated. The most common adverse effects were nausea, tremor, and generalized malaise. We conclude that mexiletine is an effective antiarrhythmic in some patients with life-threatening ventricular arrhythmias refractory to conventional drugs. Adverse effects significantly limit its use.

Original languageEnglish (US)
Pages (from-to)777-784
Number of pages8
JournalClinical Pharmacology and Therapeutics
Volume34
Issue number6
StatePublished - Dec 1983

Fingerprint

Mexiletine
Cardiac Arrhythmias
Tremor
Ventricular Fibrillation
Ventricular Tachycardia
Pharmaceutical Preparations
Nausea
Electric Stimulation
Electrocardiography

ASJC Scopus subject areas

  • Pharmacology

Cite this

Mexiletine in refractory ventricular arrhythmias. / Fenster, Paul E; Kern, Karl B.

In: Clinical Pharmacology and Therapeutics, Vol. 34, No. 6, 12.1983, p. 777-784.

Research output: Contribution to journalArticle

@article{8efa9d55f5174a0c8e1da53ef586de94,
title = "Mexiletine in refractory ventricular arrhythmias",
abstract = "The antiarrhythmic efficacy of mexiletine was evaluated in 28 subjects with recurrent ventricular tachycardia or fibrillation (22 subjects) or with symptomatic complex ventricular ectopy (six subjects). In all, either the arrhythmia was refractory to other drugs, or such therapy was not tolerated. Response to mexiletine was assessed by continuous ECGs, and in five cases by programmed electrical stimulation. Mexiletine abolished the arrhythmia in 12 cases, but was not tolerated long-term in four. Mexiletine was ineffective in 10 subjects. Seven subjects had significant adverse reactions during short-term dosing; in six, mexiletine was discontinued because of adverse effects after the first few doses so efficacy was not evaluated. The most common adverse effects were nausea, tremor, and generalized malaise. We conclude that mexiletine is an effective antiarrhythmic in some patients with life-threatening ventricular arrhythmias refractory to conventional drugs. Adverse effects significantly limit its use.",
author = "Fenster, {Paul E} and Kern, {Karl B}",
year = "1983",
month = "12",
language = "English (US)",
volume = "34",
pages = "777--784",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Mexiletine in refractory ventricular arrhythmias

AU - Fenster, Paul E

AU - Kern, Karl B

PY - 1983/12

Y1 - 1983/12

N2 - The antiarrhythmic efficacy of mexiletine was evaluated in 28 subjects with recurrent ventricular tachycardia or fibrillation (22 subjects) or with symptomatic complex ventricular ectopy (six subjects). In all, either the arrhythmia was refractory to other drugs, or such therapy was not tolerated. Response to mexiletine was assessed by continuous ECGs, and in five cases by programmed electrical stimulation. Mexiletine abolished the arrhythmia in 12 cases, but was not tolerated long-term in four. Mexiletine was ineffective in 10 subjects. Seven subjects had significant adverse reactions during short-term dosing; in six, mexiletine was discontinued because of adverse effects after the first few doses so efficacy was not evaluated. The most common adverse effects were nausea, tremor, and generalized malaise. We conclude that mexiletine is an effective antiarrhythmic in some patients with life-threatening ventricular arrhythmias refractory to conventional drugs. Adverse effects significantly limit its use.

AB - The antiarrhythmic efficacy of mexiletine was evaluated in 28 subjects with recurrent ventricular tachycardia or fibrillation (22 subjects) or with symptomatic complex ventricular ectopy (six subjects). In all, either the arrhythmia was refractory to other drugs, or such therapy was not tolerated. Response to mexiletine was assessed by continuous ECGs, and in five cases by programmed electrical stimulation. Mexiletine abolished the arrhythmia in 12 cases, but was not tolerated long-term in four. Mexiletine was ineffective in 10 subjects. Seven subjects had significant adverse reactions during short-term dosing; in six, mexiletine was discontinued because of adverse effects after the first few doses so efficacy was not evaluated. The most common adverse effects were nausea, tremor, and generalized malaise. We conclude that mexiletine is an effective antiarrhythmic in some patients with life-threatening ventricular arrhythmias refractory to conventional drugs. Adverse effects significantly limit its use.

UR - http://www.scopus.com/inward/record.url?scp=0021082397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021082397&partnerID=8YFLogxK

M3 - Article

VL - 34

SP - 777

EP - 784

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 6

ER -